Estudo terapêutico aberto com sulfato de aminosidine na leishmaniose mucosa causada for Leishmania (viannia) braziliensis

Romero, Gustavo; Lessa, Hélio A.; Macêdo, Vanize; Carvalho, Edgar M.; Barrai, Aldina; Magalhães, Albino V.; Orge, Maria G.O.; Abreu, Maria Va.; Marsden, Philip D.

doi:10.1590/s0037-86821996000600005

Cited by 17 publications

(4 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Topical formulations containing paromomycin sulfate (PA) are successful in promoting local healing in BALB/c mice and in patients with Leishmania infection [4][5][6][7][8][9][10]. However, an important drawback of these and other therapeutic approaches is the recurrence of lesions and the possible dissemination of parasites [3,[11][12][13]. In 2 studies, 10%-13% of subjects did not respond to PA topical treatment [14,15].…”

Section: Leishmaniasis a Major Disease Listed In The World Healthmentioning

confidence: 99%

Combined Interleukin‐12 and Topical Chemotherapy for Established Leishmaniasis Drastically Reduces Tissue Parasitism and Relapses in Susceptible Mice

Fernandes¹,

Carvalho

Tavares

et al. 2001

J INFECT DIS

View full text Add to dashboard Cite

The efficacy of the association of paromomycin sulfate (PA) with recombinant (r) interleukin (IL)-12 was investigated by topical treatment of BALB/c mice infected with Leishmania major that displayed fully developed cutaneous lesions. Although healing was observed in PA-treated groups, lesions recurred in 100% of these animals 70 days after treatment. In contrast, lesions were absent in a high proportion of PA- and rIL-12-treated mice 120 days after treatment. The PA/rIL-12-treated mice had a switch in cytokine response, from high IL-4 and low interferon (IFN)-gamma levels to low IL-4 and high IFN-gamma levels, and reductions in parasite load, dissemination of parasites, and inflammation. Thus, the association of rIL-12 to topical chemotherapy for leishmaniasis may be an important strategy for increasing cure rates and decreasing the incidence of relapse.

show abstract

Section: Leishmaniasis a Major Disease Listed In The World Healthmentioning

confidence: 99%

Combined Interleukin‐12 and Topical Chemotherapy for Established Leishmaniasis Drastically Reduces Tissue Parasitism and Relapses in Susceptible Mice

Fernandes¹,

Carvalho

Tavares

et al. 2001

J INFECT DIS

View full text Add to dashboard Cite

show abstract

“…As MGT calculadas excluindo os pacientes que receberam tratamentos alternativos foram 64,0; 18,9; 15,1; 24,9; 24,2 e 14,9 zero, três, seis, nove, doze e vinte e quatro meses após tratamento. Houve uma diminuição significativa entre zero e três meses (t = 6,52 p < 0,005); aumento significativo entre seis e nove meses t = -3,59 p < 0,005) e diminuição significativa entre 12 10 . Os resultados obtidos durante os dois anos de seguimento mostraram que a eficácia do tratamento da LM com uma série de 20 dias de sulfato de aminosidine é baixa (33,3%) e que está indicado o acompanhamento prolongado dos pacientes com este tipo de doença, pela possibilidade de recidiva.…”

Section: Resultsunclassified

“…A avaliação trimestral durante o primeiro ano mostrou que quatro, dos 14 pacientes com boa resposta inicial, apresentaram recidiva. A taxa de cura clínica, definida como a ausência de sinais e sintomas da doença durante o primeiro ano de acompanhamento foi 48% (10/21 pacientes) 10 . Pelas evidências que sugerem que a infecção por LVb pode persistir indefinidamente no hospedeiro humano 3 6 12 e pela observação de episódios de recidiva da doença mucosa, anos após a cura clínica 8 9 , realizou-se a procura ativa dos 21 pacientes tratados com sulfato de aminosidine dois anos após o tratamento com o objetivo de detectar possíveis recidivas e completar a avaliação sorológica.…”

unclassified

Tratamento da leishmaniose mucosa com sulfato de aminosidine: resultados de dois anos de acompanhamento

Romero

Lessa²,

Orge³

et al. 1998

Rev. Soc. Bras. Med. Trop.

Self Cite

View full text Add to dashboard Cite

In 1996, 20 of 21 patients with mucosal leishmaniasis, treated in 1994 with aminosidine sulfate, 16mg/kg/day salt, by intramuscular injection for 20 days, were clinically evaluated. One patient died due to disease not related to mucosal leishmaniasis. Seven of 14 patients (66.7% N = 21) who achieved complete remission three months after treatment remained clinically cured 24 months later and seven relapsed in the same period (50% N = 14). Sorological follow-up showed poor correlation with the results of clinical examination.

show abstract

“…However, these drugs present inconvenient aspects that limit their use, such as the necessity of parenteral administration and a high incidence of toxic and adverse reactions [2]. Pentavalent antimonials have long been considered highly effective [3], [5], however, there is a growing body of evidence of variable efficacy, depending on species, geographic region, presence of resistant strains, and therapeutic schemes [2], [6]–[8]. Among the alternative therapeutic schemes, intralesional administration of pentavalent antimonials has been used to treat old world cutaneous leishmaniasis [9].…”

Section: Introductionmentioning

confidence: 99%

Triphenylmethane Derivatives Have High In Vitro and In Vivo Activity against the Main Causative Agents of Cutaneous Leishmaniasis

et al. 2013

View full text Add to dashboard Cite

The current standard of care for cutaneous leishmaniasis (CL) is organic antimonial compounds, but the administration of these compounds is complicated by a low therapeutic - toxic index, as well as parenteral administration. Thus, there is an urgent need for the development of new and inexpensive therapies for the treatment of CL. In this study, we evaluate the activity of the triphenylmethane (TPM) class of compounds against three species of Leishmania which are pathogenic in humans. The TPM have a history of safe use in humans, dating back to the use of the original member of this class, gentian violet (GV), from the early 20th century. Initially, the in vitro efficacy against Leishmania (Viannia) braziliensis, L. (Leishmania) amazonensis and L. (L.) major of 9 newly synthesized TPM, in addition to GV, was tested. Inhibitory concentrations (IC) IC50 of 0.025 to 0.84 µM had been found in promastigotes in vitro assays. The four most effective compounds were then tested in amastigote intracellular assays, resulting in IC50 of 0.10 to 1.59 µM. A high degree of selectivity of antiparasitic activity over toxicity to mammalian cells was observed. Afterwards, GV and TPM 6 were tested in a topical formulation in mice infected with L. (L.) amazonensis leading to elimination of parasite burdens at the site of lesion/infection. These results demonstrated that TPM present significant anti-leishmanial activities and provide a rationale for human clinical trials of GV and other TPM. TPM are inexpensive and safe, thus using them for treatment of CL may have a major impact on public health.

show abstract

Estudo terapêutico aberto com sulfato de aminosidine na leishmaniose mucosa causada for Leishmania (viannia) braziliensis

Cited by 17 publications

References 19 publications

Combined Interleukin‐12 and Topical Chemotherapy for Established Leishmaniasis Drastically Reduces Tissue Parasitism and Relapses in Susceptible Mice

Combined Interleukin‐12 and Topical Chemotherapy for Established Leishmaniasis Drastically Reduces Tissue Parasitism and Relapses in Susceptible Mice

Tratamento da leishmaniose mucosa com sulfato de aminosidine: resultados de dois anos de acompanhamento

Triphenylmethane Derivatives Have High In Vitro and In Vivo Activity against the Main Causative Agents of Cutaneous Leishmaniasis

Contact Info

Product

Resources

About